April 11th 2024
The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
What Employers Can Do to Stand Up for Biosimilar Formulary Placement
February 24th 2022A report from the National Alliance of Healthcare Purchaser Coalitions detailed the common concerns employers have regarding implementing biosimilars within their health care plans and outlined how they could take charge and make a difference.
Biosimilars CEOs: Opportunities Abound, but Regulatory, “Branding” Hurdles Remain
February 24th 2022There remains risk in the US market due to regulatory and legal hurdles—not to mention a combative political environment, according to executives who gathered last week during the “CEOs Unplugged” session at Access! 2022, held by the Association for Accessible Medicines (AAM) in Orlando.
The Biosimilars Forum's Julie Reed Shares Her Major Goals for the Organization in New Role
February 13th 2022Improving access and getting big legislative changes for biosimilars passed are just some of the many plans that Julie M. Reed, the new executive director of the Biosimilars Forum, has for the organization.
Biogen, Xbrane Enter Commercialization Agreement for Cimzia Biosimilar
February 10th 2022Biogen and Xbrane Biopharma signed a commercialization agreement for Xcimzane, a certolizumab pegol biosimilar referencing Cimzia for the treatment of rheumatoid arthritis, psoriasis, and other rheumatologic conditions.
Alvotech Enters Licensing Agreement With BiosanaPharma for Development of Biosimilar for Xolair
February 2nd 2022Xolair, the only currently approved product containing omalizumab, was first approved in 2003. AVT23 is an investigational compound and has not received regulatory approval in any country. Current sales of Xolair are estimated at $3.3 billion.
The Biosimilars Forum Announces Julie Reed as New Executive Director
January 31st 2022The non-profit organization dedicated to the advancement of biosimilars has appointed Cofounder and President Juliana (Julie) M. Reed, as the new executive director. Reed shared some of her goals for the Biosimilars Forum in an interview with The Center for Biosimilars®.
Wayne Winegarden, PhD: How to Ensure Biosimilar Affordability as Reference Drug Prices Increase
January 30th 2022Wayne Winegarden, PhD, a senior fellow in business and economics at Pacific Research Institute, discusses how to ensure affordability of adalimumab biosimilars when they enter the market as AbbVie continues to raise the price of the reference product (Humira).
What's Holding Up Biosimilar Uptake? Misconceptions, Misaligned Incentives, Panelists Say
January 26th 2022US biosimilar uptake faces several barriers, including misconceptions regarding biosimilar efficacy and a misalignment of prescription incentives between payers, providers, and patients, panelists discussed.
Robert Popovian, PharmD, MS, Discusses Biosimilar Progress and Education in the United States
January 12th 2022As chief science policy officer for Global Healthy Living Foundation, Robert Popovian, PharmD, MS, has a bird’s-eye view of some of the central issues of biosimilar access in the United States.